Prescribing preferences and personal experience of female gynaecologists in Germany and Austria regarding use of extended-cycle oral contraceptives

Inka Wiegratz; Katrin Galiläer; Nicole Sänger; Achim Rody; Herbert Kühl; E Schleußner

doi:10.3109/13625187.2010.518708

Prescribing preferences and personal experience of female gynaecologists in Germany and Austria regarding use of extended-cycle oral contraceptives

Inka Wiegratz, Katrin Galiläer, Nicole Sänger, Achim Rody, Herbert Kühl, E Schleußner

In: The European Journal of Contraception & Reproductive Health Care · 2010 · vol. 15(6) , pp. 405–412 · doi:10.3109/13625187.2010.518708 · PMID:20863264 · W2020094257

article OA: closed CC0

View on OpenAlex View on PubMed View at publisher

⚙ AI-generated summary by claude@2026-06, 2026-06-11 ⓘ

German and Austrian female gynecologists widely prescribe and personally use extended-cycle oral contraceptives for medical reasons, regardless of their own extended-cycle use experience.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVES: To investigate prescribing preferences and personal experience of female gynaecologists with extended-cycle use of combined oral contraceptives (COCs) in Germany and Austria. METHODS: A questionnaire on prescribing patterns and personal experience with extended COC regimens was delivered to female gynaecologists practising in Germany and Austria. RESULTS: Of 2,500 delivered questionnaires, 1,113 were returned. After exclusion of 22 invalid questionnaires, the remaining 1,091 (43.6% of delivered questionnaires) remained eligible for analysis and were considered as the full analysis set (100%). Nearly all gynaecologists (97%) reported prescription of extended-cycle regimens to their patients, independent of their personal experience as users. The main medical reasons for prescription were cycle-related headache (93.8%), dysmenorrhoea (88.2%), cycle-related complaints (74.5%), and hypermenorrhoea (70.9%). In total, 863 gynaecologists had personally used COCs, 321 (37.2%) in extended-cycle regimen. The most commonly employed combinations were 30 μg ethinylestradiol (EE) + 2 mg dienogest (n = 114; 37.5%) and 30 μg EE + 3 mg drospirenone (n = 69; 22.7%). CONCLUSIONS: Although considered off-label use, extended-cycle use of COCs is widely prescribed and personally used by German and Austrian female gynaecologists. The lack of personal experience with extended-cycle use does not impair the prescribing habit of gynaecologists with regard to extended-cycle regimens.

My notes (saved in your browser only)

Condition tags

dysmenorrhea

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (25)

Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on lipid metabolism during 1 year of conventional or extended-cycle use via openalex
Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on thyroid hormones and androgen parameters: conventional vs. extended-cycle use via openalex
Effects of Combined Oral Contraceptive Ethinylestradiol (30 μg) and Dienogest (2 mg) on Carbohydrate Metabolism During 1 Year of Conventional or Extended-Cycle Use via openalex
Effects of conventional or extended-cycle regimen of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on various hemostasis parameters via openalex
Extended and Continuous Use of Hormonal Contraceptives to Reduce Menstruation via openalex
Non-contraceptive health benefits of oral contraceptives via openalex
doi:10.1358/dot.2008.44.3.1197950 via openalex
doi:10.1080/13625180701800672 via openalex
doi:10.1016/j.contraception.2007.01.014 via openalex
doi:10.1016/j.ajog.2004.02.012 via openalex
doi:10.1016/s0029-7844(03)00014-0 via openalex
doi:10.1016/j.ajog.2006.02.048 via openalex
doi:10.1016/s0029-7844(99)00524-4 via openalex
doi:10.1016/j.jadohealth.2006.09.013 via openalex
doi:10.1016/j.contraception.2009.05.004 via openalex
doi:10.1016/j.contraception.2005.07.001 via openalex
doi:10.1016/s0010-7824(03)00141-0 via openalex
doi:10.1016/j.contraception.2007.02.005 via openalex
doi:10.1016/j.contraception.2003.09.004 via openalex
doi:10.1016/j.contraception.2006.07.005 via openalex
doi:10.1016/j.contraception.2004.06.008 via openalex
doi:10.1016/0010-7824(90)90050-6 via openalex
doi:10.2165/00003495-200464210-00006 via openalex
doi:10.1016/j.contraception.2005.09.009 via openalex
doi:10.1016/j.contraception.2010.06.015 via openalex

Source provenance

openalex: last seen: 2026-05-11T06:40:38.933960+00:00

License: CC0 · commercial use OK

[1] Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on lipid metabolism during 1 year of conventional or extended-cycle use via openalex

[2] Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on thyroid hormones and androgen parameters: conventional vs. extended-cycle use via openalex

[3] Effects of Combined Oral Contraceptive Ethinylestradiol (30 μg) and Dienogest (2 mg) on Carbohydrate Metabolism During 1 Year of Conventional or Extended-Cycle Use via openalex

[4] Effects of conventional or extended-cycle regimen of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on various hemostasis parameters via openalex

[5] Extended and Continuous Use of Hormonal Contraceptives to Reduce Menstruation via openalex

[6] Non-contraceptive health benefits of oral contraceptives via openalex

[7] doi:10.1358/dot.2008.44.3.1197950 via openalex

[8] doi:10.1080/13625180701800672 via openalex

[9] doi:10.1016/j.contraception.2007.01.014 via openalex

[10] doi:10.1016/j.ajog.2004.02.012 via openalex

[11] doi:10.1016/s0029-7844(03)00014-0 via openalex

[12] doi:10.1016/j.ajog.2006.02.048 via openalex

[13] doi:10.1016/s0029-7844(99)00524-4 via openalex

[14] doi:10.1016/j.jadohealth.2006.09.013 via openalex

[15] doi:10.1016/j.contraception.2009.05.004 via openalex

[16] doi:10.1016/j.contraception.2005.07.001 via openalex

[17] doi:10.1016/s0010-7824(03)00141-0 via openalex

[18] doi:10.1016/j.contraception.2007.02.005 via openalex

[19] doi:10.1016/j.contraception.2003.09.004 via openalex

[20] doi:10.1016/j.contraception.2006.07.005 via openalex

[21] doi:10.1016/j.contraception.2004.06.008 via openalex

[22] doi:10.1016/0010-7824(90)90050-6 via openalex

[23] doi:10.2165/00003495-200464210-00006 via openalex

[24] doi:10.1016/j.contraception.2005.09.009 via openalex

[25] doi:10.1016/j.contraception.2010.06.015 via openalex